Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- PTGX
- Price
- 84.79
- Stock movement down
- -0.16 (-0.18%)
- Company name
- Protagonist Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 5.45B
- Ent value
- 5.39B
- Price/Sales
- 26.05
- Price/Book
- 8.44
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 118.72
- Forward P/E
- 82.14
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 126.38%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-05
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PTGX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 118.72 |
| Price to OCF | 83.25 |
| Price to FCF | 85.54 |
| Price to EBITDA | 197.97 |
| EV to EBITDA | 195.88 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 26.05 |
| Price to Book | 8.44 |
| EV to Sales | 25.78 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 62.52M |
| EPS (TTM) | 0.72 |
| FCF per share (TTM) | 1.00 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 209.22M |
| Gross profit (TTM) | 209.22M |
| Operating income (TTM) | 19.01M |
| Net income (TTM) | 45.91M |
| EPS (TTM) | 0.72 |
| EPS (1y forward) | 1.06 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | 9.09% |
| Profit margin (TTM) | 21.94% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 113.71M |
| Net receivables | 583.00K |
| Total current assets | 586.42M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 20.21M |
| Total assets | 701.69M |
| Accounts payable | 5.65M |
| Short/Current long term debt | 10.75M |
| Total current liabilities | 44.94M |
| Total liabilities | 56.25M |
| Shareholder's equity | 645.44M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 65.47M |
| Capital expenditures (TTM) | 1.76M |
| Free cash flow (TTM) | 63.71M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 7.11% |
| Return on Assets | 6.54% |
| Return on Invested Capital | 7.09% |
| Cash Return on Invested Capital | 9.84% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 86.54 |
| Daily high | 88.16 |
| Daily low | 85.19 |
| Daily Volume | 752K |
| All-time high | 95.35 |
| 1y analyst estimate | 96.33 |
| Beta | 2.19 |
| EPS (TTM) | 0.72 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 18 Mar 2026 |
Downside potential
Loading...
Downside potential data
| PTGX | S&P500 | |
| Current price drop from All-time high | -11.07% | -0.89% |
| Highest price drop | -31.58% | -19.00% |
| Date of highest drop | 10 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -12.94% | -2.49% |
| Avg time to new high | 18 days | 6 days |
| Max time to new high | 117 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
5.45B
Marketcap category
Mid-cap
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Employees
128
Investor relations
-
SEC filings
CEO
Dinesh V. Patel
Country
USA
City
Newark
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page